503B Tirzepatide Rules
Outsourcing facilities and federal oversight.
Outsourcing facilities and federal oversight.
Across the 17 programmes we price, all-in cost runs from $133 a month at the starter dose, with the cheapest first year at about $2,580 (NexLife, $215 a month at a 10 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
All-in monthly cost at 10 mg
How to verify this yourself
Regulatory summaries age badly, this one included. FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
Proposal, enforcement, or rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is about claims rather than a finding of patient harm. Only a final rule changes what is lawful. If a regulatory story is being used to sell you something urgently, the urgency is the marketing.
What it changes for a patient
Rarely the prescription requirement, the pharmacy licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Proposal, enforcement, or final rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is a formal statement that specific claims are unlawful, not a finding of patient harm. Only a final rule changes what may lawfully be done.
If a regulatory story is being used to sell you something urgently, the urgency is the marketing. Nothing in this category has ever required a same-day decision from a patient.
How to verify any of this yourself
FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. State boards publish their own actions. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
What regulatory change does and does not touch
It rarely changes the prescription requirement, the pharmacy licensing framework or the clinical review. It routinely changes price, which programmes operate, and what may be compounded at scale. Several large platforms left the compounded market during 2026 for exactly these reasons.
The practical defences are boring: do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 17 programmes we price, that runs from $215 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
6 of those programmes charge a recurring platform fee on top of medication and 11 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
11 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded tirzepatide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
How to check this against the primary record
Regulatory summaries age badly, this one included. FDA publishes its compounding pages, its shortage database and its warning letters, all free and searchable by company name. Where this page and the agency disagree, the agency is right.
Three things get conflated in coverage of this area: a proposal, an enforcement action and a final rule. Only the third changes what is lawful.
What it changes for someone paying cash
Rarely the prescription requirement, the licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Five large programmes stopped selling compounded tirzepatide during 2026 and patients generally found out at renewal.
The practical response is unglamorous: do not let supply run to zero, keep a prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Why regulatory news is used as a sales tool
Because urgency sells. A programme citing a rule change to push you into a twelve-month prepayment is using a genuine regulatory fact to manufacture a deadline that does not apply to you. Read the rule, not the email about the rule.
Reading 503b tirzepatide rules against the rest of the decision
This sits inside a decision with three parts: what you will pay at the dose you hold, who makes what you are injecting, and what happens if you stop. Most published guidance covers the first and treats the other two as footnotes.
They are not footnotes. A price advantage of a few hundred dollars a year is erased by one interrupted month, and an interrupted month is a clinical event rather than an inconvenience — the withdrawal evidence for this drug class is unambiguous about what follows a gap.
Which is why this section exists separately from the pricing pages, and why the verification steps on it are worth completing even when the programme you are considering is the cheapest one on the site.
What to do with this before you enrol
Turn it into two or three questions you can send in an email. Anything on this page that cannot be converted into a question a programme could answer in writing is context rather than a check, and context does not protect you.
The programmes that answer promptly and specifically are, in our reading of the public record, rarely the ones patients later write about. That is a weak signal rather than evidence, but it costs nothing to collect and it arrives before your money does.
If a programme declines to answer, that is an answer. The market currently offers 17 priced alternatives, the cheapest verified at $215 a month all-in at a maintenance dose.
The failure mode this section is guarding against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew. A prepaid rate when you will pay monthly.
Each of those errors is small individually and they compound in the same direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated.
Priced correctly, the cheapest verified route sits at $215 a month all-in at a maintenance dose. Anything materially below that band deserves the question of which distortion is producing it.
Why we publish the working rather than a verdict
A single recommendation is more useful to read and less useful to act on, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and the rankings state their sort key. If you disagree with our weighting, take the file and weight it differently — that is what publishing it is for.
What would make this page wrong
A price change we have not captured, a programme leaving the market, or a figure we recorded from a third party that does not survive checking. All three have happened during 2026 and all three are logged when they do.
Prices here were captured 2026-08-05. Treat anything older than a month as needing a re-check against the provider's own page, which every programme record links directly.
Putting 503b tirzepatide rules in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting any one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 17 programmes publish a price we could capture, spanning $215 to $548 a month all-in at a maintenance dose. Against a spread that wide, most optimisation attempted at the margins is worth less than getting the basis right once.
What good looks like
A programme that states a figure at a named dose, names the pharmacy behind it, publishes cancellation terms before payment, and says plainly that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority of the market does all four.
The cheapest verified route sits at $215 a month all-in, which establishes that disclosure and low price are not in tension. Programmes publishing more are not systematically dearer — which undercuts the usual explanation for withholding.
What to do next
Narrow to two or three on the criterion that actually binds for you, open the individual reviews, and send each the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel, and what is refundable.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.